Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

10 questions · 10 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 10 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Antidepressants (trazodone 200 mg/day) vs placebo

Frequency of adverse effects ‐ dizziness ( · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dizziness compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Adverse event: tremor · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: tremor compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Abdominal pain · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: abdominal pains compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: headache compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Adverse effects: urinary incontinence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: urinary incontinence compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: drowsiness compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Adverse effects: palpitations · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: palpitations compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Adverse effects: dry mouth · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dry mouth compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months)
    SoF1. Change in QoL short-term (mean Beck Depression Inventory, 0-63, lower better): this single study narratively reported that both intervention and placebo participants were less depressed at trial completion, but…
    1 study · 37 participants
    Very low